Free Trial

Zentalis Pharmaceuticals (ZNTL) News Today

Zentalis Pharmaceuticals logo
$1.28 -0.07 (-5.17%)
Closing price 04/3/2025 04:00 PM Eastern
Extended Trading
$1.29 +0.01 (+0.39%)
As of 07:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Zentalis Pharmaceuticals, Inc. stock logo
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Rating of "Hold" by Brokerages
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) has received an average rating of "Hold" from the nine brokerages that are covering the firm, MarketBeat.com reports. Five equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommenda
Leerink Partnrs Issues Negative Estimate for ZNTL Earnings
HC Wainwright Has Bearish Forecast for ZNTL Q1 Earnings
Zentalis Pharmaceuticals, Inc. stock logo
What is HC Wainwright's Forecast for ZNTL Q1 Earnings?
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - Stock analysts at HC Wainwright dropped their Q1 2025 earnings per share (EPS) estimates for Zentalis Pharmaceuticals in a research report issued to clients and investors on Thursday, March 27th. HC Wainwright analyst A. Fein now foreca
Zentalis Pharmaceuticals, Inc. stock logo
Leerink Partnrs Has Pessimistic Outlook of ZNTL Q1 Earnings
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - Equities research analysts at Leerink Partnrs dropped their Q1 2025 earnings per share estimates for shares of Zentalis Pharmaceuticals in a research report issued on Wednesday, March 26th. Leerink Partnrs analyst A. Berens now anticipa
Zentalis Pharmaceuticals, Inc. stock logo
Wedbush Reaffirms Neutral Rating for Zentalis Pharmaceuticals (NASDAQ:ZNTL)
Wedbush reissued a "neutral" rating and issued a $4.00 price target on shares of Zentalis Pharmaceuticals in a report on Friday.
Zentalis Pharmaceuticals, Inc. stock logo
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Posts Earnings Results, Beats Expectations By $0.09 EPS
Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) posted its earnings results on Wednesday. The company reported ($0.66) EPS for the quarter, topping analysts' consensus estimates of ($0.75) by $0.09. The firm had revenue of $26.90 million for the quarter.
Zentalis Pharmaceuticals, Inc. stock logo
HC Wainwright Reaffirms Buy Rating for Zentalis Pharmaceuticals (NASDAQ:ZNTL)
HC Wainwright reiterated a "buy" rating and issued a $10.00 target price on shares of Zentalis Pharmaceuticals in a research note on Thursday.
Zentalis Pharmaceuticals, Inc. stock logo
Zentalis Pharmaceuticals' (ZNTL) "Buy" Rating Reaffirmed at HC Wainwright
HC Wainwright reaffirmed a "buy" rating and set a $10.00 target price on shares of Zentalis Pharmaceuticals in a research report on Monday.
Zentalis presents updated clinical data on azenosertib as SGO 2025
Zentalis Pharmaceuticals, Inc. stock logo
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of "Hold" from Brokerages
Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) have received a consensus rating of "Hold" from the nine analysts that are currently covering the stock, Marketbeat reports. Five analysts have rated the stock with a hold rating and four have given a buy rating to the compan
10 Cheapest Stocks Insiders Are Buying Recently
Zentalis Pharmaceuticals, Inc. stock logo
Zentalis Pharmaceuticals (ZNTL) Expected to Announce Quarterly Earnings on Tuesday
Zentalis Pharmaceuticals (NASDAQ:ZNTL) will be releasing earnings before the market opens on Tuesday, February 25.
Zentalis Pharmaceuticals, Inc. stock logo
Insider Buying: Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Insider Buys 20,000 Shares of Stock
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) insider Ingmar Bruns bought 20,000 shares of the stock in a transaction dated Thursday, February 6th. The stock was bought at an average cost of $2.28 per share, with a total value of $45,600.00. Following the purchase, the insider now owns 36,629 shares in the company, valued at $83,514.12. The trade was a 120.27 % increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Zentalis Pharmaceuticals, Inc. stock logo
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Rating of "Hold" by Analysts
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) has received a consensus rating of "Hold" from the nine research firms that are presently covering the stock, MarketBeat.com reports. Five analysts have rated the stock with a hold rating and four have issued a buy rating on the compa
Zentalis Pharmaceuticals, Inc. stock logo
Q3 Earnings Forecast for ZNTL Issued By Leerink Partnrs
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - Investment analysts at Leerink Partnrs issued their Q3 2025 earnings per share estimates for shares of Zentalis Pharmaceuticals in a research report issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens expects that the c
Zentalis Pharmaceuticals, Inc. stock logo
Q1 Earnings Forecast for ZNTL Issued By Leerink Partnrs
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of Zentalis Pharmaceuticals in a note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst A. Berens anticipates that the company will post
Zentalis Pharmaceuticals, Inc. stock logo
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Director Jan Skvarka Purchases 60,000 Shares
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) Director Jan Skvarka bought 60,000 shares of the stock in a transaction dated Friday, January 31st. The stock was bought at an average price of $1.72 per share, with a total value of $103,200.00. Following the acquisition, the director now owns 149,551 shares in the company, valued at approximately $257,227.72. This represents a 67.00 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.
Zentalis Pharmaceuticals, Inc. stock logo
HC Wainwright Issues Optimistic Forecast for ZNTL Earnings
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - Equities research analysts at HC Wainwright boosted their Q1 2025 earnings per share (EPS) estimates for Zentalis Pharmaceuticals in a report released on Wednesday, January 29th. HC Wainwright analyst A. Fein now expects that the compan
Zentalis Pharmaceuticals, Inc. stock logo
Leerink Partnrs Issues Positive Estimate for ZNTL Earnings
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - Stock analysts at Leerink Partnrs raised their FY2024 earnings per share estimates for Zentalis Pharmaceuticals in a research report issued to clients and investors on Wednesday, January 29th. Leerink Partnrs analyst A. Berens now antic
Zentalis Pharmaceuticals, Inc. stock logo
Equities Analysts Set Expectations for ZNTL FY2024 Earnings
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - Analysts at Wedbush lifted their FY2024 earnings estimates for shares of Zentalis Pharmaceuticals in a report released on Wednesday, January 29th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings per share o
Zentalis Pharmaceuticals, Inc. stock logo
FY2029 Earnings Forecast for ZNTL Issued By HC Wainwright
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Zentalis Pharmaceuticals in a research report issued on Wednesday, January 29th. HC Wainwright analyst A. Fein anticipates that the company will post earnings of (
Zentalis Pharmaceuticals, Inc. stock logo
Equities Analysts Offer Predictions for ZNTL FY2029 Earnings
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - Investment analysts at Wedbush issued their FY2029 earnings per share estimates for shares of Zentalis Pharmaceuticals in a report issued on Wednesday, January 29th. Wedbush analyst R. Driscoll forecasts that the company will post earni
Remove Ads
Get Zentalis Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ZNTL and its competitors with MarketBeat's FREE daily newsletter.

ZNTL Media Mentions By Week

ZNTL Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ZNTL
News Sentiment

-0.08

0.61

Average
Medical
News Sentiment

ZNTL News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ZNTL Articles
This Week

17

3

ZNTL Articles
Average Week

Remove Ads
Get Zentalis Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ZNTL and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:ZNTL) was last updated on 4/4/2025 by MarketBeat.com Staff
From Our Partners